LCS
AQST icon

Levin Capital Strategies’s Aquestive Therapeutics AQST Stock Holding History

Levin Capital Strategies’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-45,000
Closed -$131K – 202
2025
Q1 		$131K Buy
45,000
+25,000
+125% +$75.7K 0.01% 167
2024
Q4 		$71.2K Sell
20,000
-15,000
-43% -$69.2K 0.01% 212
2024
Q3 		$174K Buy
+35,000
New +$136K 0.02% 196

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Levin Capital Strategies's AQST Position: Q2 2025 in Review

Levin Capital Strategies sold out of Aquestive Therapeutics (AQST) in Q2 2025, closing a stake of 45,000 shares — an estimated $131K sold.

Levin Capital Strategies first reported a position in AQST in Q3 2024 and held it in 3 quarters. The position peaked at $174K in Q3 2024. 116 funds tracked by Wall St. Rank hold AQST as of Q2 2025.

  • Levin Capital Strategies reported no remaining Aquestive Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Levin Capital Strategies sold 45,000 Aquestive Therapeutics shares in Q2 2025, an estimated $131K.
  • Levin Capital Strategies first reported a position in Aquestive Therapeutics in Q3 2024 and held it in 3 quarters.
  • Levin Capital Strategies's Aquestive Therapeutics position peaked at $174K in Q3 2024.
  • 116 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2025.

Based on Levin Capital Strategies's 13F filing for Q2 2025, filed 5 Aug 2025.